OpenAI's Pentagon Deal, Anthropic Ban Backlash, and AI's Next Medical Breakthrough

Host Dusty Porter covers three AI stories: OpenAI signing a Pentagon deal just hours after President Trump ordered agencies to cut ties with Anthropic over its refusal to support mass domestic surveillance and autonomous weapons, while noting reports that the Pentagon still used Claude in Middle East strikes; Sam Altman says the deal was rushed, the optics look bad, and calls the Anthropic ban a poor decision, as consumer backlash pushes Claude to #1 on Apple's App Store and "cancel ChatGPT" trends. He also discusses OpenAI raising $110B at a $730B valuation led by Amazon, with Nvidia and SoftBank participating. Finally, he highlights Generate:Biomedicines' $425M Nasdaq IPO and its AI-designed severe-asthma antibody GB0895 entering phase three trials, arguing AI could accelerate medical breakthroughs.